Navigation Links
Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
Date:10/18/2010

WORCESTER, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com) announced today that Dr. Joseph Rubinfeld, an independent scientific advisor to the Company and a member of the Company's Scientific Advisory Board, issued the following statement in respect of the reverse stock split proposal being considered at today's special meeting of the Generex stockholders:

"Having been intimately involved in the drug development world for over 40 years, I have hands-on experience with the dilemma faced by Generex and its shareholders on the day of this important vote.  Many shareholders have personal experience with a reverse split or a delisting which has helped to shape their opinion on how to vote. Still others may look to point the finger of blame at management regardless of the current management's role in arriving at this point. I believe that it is important for every shareholder at this time to carefully consider the future in casting their vote as opposed to looking in the rear view mirror.  I myself am confident that Generex has the ability to become a powerful force in immunotherapeutic vaccines and delivery of metabolic drug therapies but, there is still work ahead.  That work includes further clinical trials and, in time, collaboration with larger pharmaceutical companies.  As we continue to do this work we will look to the capital markets and there is no doubt that our financing opportunities will be more advantageous to our current shareholder base as a NASDAQ listed company.  The same holds true when negotiating with potential partners. Generex stock is at a crossroads and I believe that approving the reverse split proposal is at this time in the best interest for the company and its stockholders as in the long term it will place the company on a more solid footing and result in much less overall dilution.  I urge all who have not v
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
7. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
11. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Md. (PRWEB) January 22, 2015 ... its new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength ... high-quality instrument is ideal for applications in a ... life science. , The user-friendly UV-1280 enables intuitive ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... BASEL, Switzerland, March 26 Roche (SWX: ROG.VX; RO.S, ... Investments USA Inc., completed its tender offer for the ... ). The offer expired at midnight, New York City ... total of approximately 395.7 million shares of Genentech common ...
... Hello, , The investor ... has,been webcasted. The presentation is available in English from ... , a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e , (Due ... necessary to copy and paste,this hyperlink into your Internet ...
... BROOMFIELD, Colo., March 25 Accera, Inc., a biotechnology ... disorders, today announced that the company will be participating ... Founder, President and CEO, will speak at the 2nd ... a.m. EDT at the Sheraton Boston Hotel in Boston, ...
Cached Biology Technology:Roche Completes Tender Offer for Genentech 2Roche Completes Tender Offer for Genentech 3Accera, Inc. to Present at Upcoming Investor Conferences 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... PHILADELPHIA Results of a new study confirm trends ... certain cancers and worse cancer outcomes if they live in ... their homelands. "Hispanics are not all the same ... M.D., Ph.D., M.Sc., researcher in the Department of Epidemiology at ...
... breast or ovarian cancer are choosing to undergo surgery as ... a report in Cancer Epidemiology, Biomarkers & Prevention , ... "Women have their breasts or ovaries removed based on their ... a genetic test result and can take more than seven ...
... Most people who carry a genetic mutation for a ... phenomenon that has puzzled scientists since the first genetic ... The Feinstein Institute for Medical Research have figured out ... the disorder they have an additional lesion that ...
Cached Biology News:Moving to the US increases cancer risk for Hispanics 2Moving to the US increases cancer risk for Hispanics 3Women often opt to surgically remove their breasts, ovaries to reduce cancer risk 2Women often opt to surgically remove their breasts, ovaries to reduce cancer risk 3Abnormal brain circuits may prevent movement disorder 2
Polyclonal Antibody to AHI1 / Jouberin...
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Biology Products: